Respiratory Flow Chip is widest panel in the market for the identification of pathogens causing acute respiratory tract infections with 23 pathogens including virus, bacteria and two targets for SARS-Cov-2. based on amplification by multiplex PCR and specific hybridization on macroarrays through our patented DNA FLOW® technology. Fully automated with minimum hands-on time.

More Less

RESPIRATORY FLOW CHIP

DNA FLOW EN

Product category: Laboratory equipment, Diagnostic tests for cancer, Other haematology / histology / cytology testing, Bacteriology testing in microbiology, Parasitology testing in microbiology, Other microbiology testing, Microbiological diagnosis, virology, equipment and systems for, DNA testing, Molecular biomarkers, Polymerase chain reaction (PCR), Other molecular diagnostics testing

HPV DIRECT FLOW CHIP

Full genotyping of human papillomavirus (HPV) based on amplification by multiplex PCR and specific hybridization on macroarrays through our patented DNA FLOW® technology. Detection of infections and coinfections of 35 genotypes with no DNA extraction needed. Fully automated solution with minimum hands-on time. All the controls are included, no extra reagents needed. Validated for LBC, FFPE and swabs.

More Less

HPV DIRECT FLOW CHIP

Flyer HPV Direct Flow Chip

Product category: Bacteriology testing in microbiology, Parasitology testing in microbiology, Other microbiology testing, Bacteriology testing, Microbiological diagnosis, virology, equipment and systems for, DNA testing, Molecular biomarkers, Polymerase chain reaction (PCR), Other molecular diagnostics testing, Other diagnostics

STD DIRECT FLOW CHIP

Detection of 12 pathogens responsible for sexually transmitted diseases (STD) through multiplex PCR and reverse hybridization based on a methodology consisting of the simultaneous amplification of bacterial, viral and protozoal DNA by multiplex PCR in only one step and directly from cellular extracts (no extraction needed), followed by hybridization on macroarrays through our patented DNA FLOW® technology. Fully automated solution with minimum hands-on time. All the controls are included, no extra reagents needed.

More Less

STD DIRECT FLOW CHIP

STD DIRECT FLOW CHIP - Flyer

SEPSIS FLOW CHIP

Simultaneous detection of 36 bacterial species Gram-positive and Gram-negative, fungus and 20 antibiotic resistance genes through multiplex PCR and reverse hybridization on macroarrays through our patented DNA FLOW® technology. No extraction needed. Fully automated solution with minimum hands-on time. All the controls are included, no extra reagents needed.

More Less

SEPSIS FLOW CHIP

SEPSIS FLOW CHIP - Flyer

AMR DIRECT FLOW CHIP

Simultaneous detection of 20 antibiotic resistance genes present in Gram-positive and Gram-negative bacteria through multiplex PCR and reverse hybridization on macroarrays through our patented DNA FLOW® technology. Fully automated solution with minimum hands-on time. All the controls are included, no extra reagents needed. Validated on nasopharyngeal and rectal swabs, perfect to detect non-symptomatic carriers.

More Less

AMR DIRECT FLOW CHIP

AMR DIRECT FLOW CHIP - Flyer

BACTERIAL CNS FLOW CHIP

Simultaneous detection of bacteria and fungus causing CNS infections through multiplex PCR and reverse hybridization on macroarrays through our patented DNA FLOW® technology. Fully automated solution with minimum hands-on time. All the controls are included, no extra reagents needed.

More Less

BACTERIAL CNS FLOW CHIP

BACTERIAL CNS FLOW CHIP - Flyer

TICK-BORNE BACTERIA FLOW CHIP

Simultaneous detection of 7 tick-borne bacteria genera through multiplex PCR and reverse hybridization on macroarrays through our patented DNA FLOW® technology. Fully automated solution with minimum hands-on time. All the controls are included, no extra reagents needed.

More Less

TICK-BORNE BACTERIA FLOW CHIP

TICK-BORNE BACTERIA FLOW CHIP - Flyer

Product category: Laboratory equipment, Slide stainers, automatic dyeing units, Immuno assay testing, Diagnostic tests for cancer, Other equipment for immunochemistry and immunology, Other haematology / histology / cytology testing

IHC antibodies

More than 300 CE IVD marked antibodies in both concentrated and Ready To Use format to perform Inmunochemistry techniques. These antibodies can be used either manually or fully automated in our fully automated platform MD-Stainer. The antibodies are also compatible with all the automated platforms in the market (Ventana, Bond, Autostainer…).

More Less

IHC antibodies

IHC antibodies - Full catalogue

Product category: Slide stainers, automatic dyeing units, Immuno assay testing, Diagnostic rapid tests, Diagnostic tests for cancer, Other equipment for immunochemistry and immunology, Other haematology / histology / cytology testing, DNA testing, Molecular biomarkers

FISH probes

19 CE IVD FISH probes for detection of solid tumors and 30 CE IVD Oncohematology FISH probes. For both manual and automated use.

More Less

FISH probes

FISH probes - Full catalogue

Product category: Laboratory equipment, Pipetting devices, pipetting equipment, Sampling systems, Slide stainers, automatic dyeing units, Other laboratory equipment, Immuno assay testing, Diagnostic tests for cancer, Other equipment for immunochemistry and immunology, Other haematology / histology / cytology testing

MD Stainer

Fully automated stainer for IHC, CISH and FISH (from dewaxing to counter-staining) consisting in 36 completely independent modules. Includes toxic waste separation and minimum volume per run.

More Less

MD Stainer

MD Stainer EN

Product category: Laboratory equipment, Pipetting devices, pipetting equipment, Sampling systems, Other laboratory equipment, Diagnostic rapid tests, Diagnostic tests for cancer, Bacteriology testing in microbiology, Parasitology testing in microbiology, Other microbiology testing, Bacteriology testing, Microbiological diagnosis, virology, equipment and systems for, DNA testing, Molecular biomarkers, Polymerase chain reaction (PCR), Other molecular diagnostics testing, Other diagnostics

Hybrispot 12 PCR Auto

Fully automated platform valid to perform DNA Flow techniques from PCR to final report. All reagents are ready to use. Minimum hands-on time.

More Less

Hybrispot 12 PCR Auto

Hybrispot 12 PCR Auto - Catalogue

Product category: Other microbiology testing, Microbiological diagnosis, virology, equipment and systems for, DNA testing, Molecular biomarkers, Polymerase chain reaction (PCR), Other molecular diagnostics testing, Other diagnostics

SARS-Cov-2 RT-PCR Kit

One step Multiplex Real Time PCR Kit for the detection of SARS-Cov-2 with 3 targets (N gene, E gene and RNAseP as Internal control). Available in Ready to Use Lyophilized format. Characterized according to WHO recommendations. Evaluated by the Calos III-CNM Health Institute with 100% of specificity and sensitivity. limit of detection 10 copies/reaction. Includes UNG enzyme to avoid contaminations and the kit is open system compatible with the most common extraction systems and RT-PCR platforms of the market.

More Less

SARS-Cov-2 RT-PCR Kit

SARS-Cov-2 RT-PCR Kit - Flyer

Product category: Diagnostic rapid tests, Other microbiology testing, Microbiological diagnosis, virology, equipment and systems for, DNA testing, Molecular biomarkers, Polymerase chain reaction (PCR), Other molecular diagnostics testing, Other diagnostics

FLU-COVID RT-PCR kit

One step Multiplex Real Time PCR Kit for the detection of Influenza A, Influenza B and SARS-Cov-2 in the same reaction (including an Internal control). Available in Ready to Use Lyophilized format. Characterized according to WHO recommendations. Evaluated by the Calos III-CNM Health Institute with 100% of specificity and sensitivity. limit of detection 10 copies/reaction. Includes UNG enzyme to avoid contaminations and the kit is open system compatible with the most common extraction systems and RT-PCR platforms of the market.

More Less

FLU-COVID RT-PCR kit

FLU-COVID RT-PCR kit - Flyer

RESPIPLEX RT-PCR Kit

One step Multiplex Real Time PCR Kit for the detection of Rhinovirus, RSV and Metapneumovirus (including an Internal control). Compatible with both SARS-Cov-2 RT-PCR Kit and FLU-COVID RT-PCR Kit in the same PCR program. Available in Ready to Use Lyophilized format. Characterized according to WHO recommendations. Evaluated by the Calos III-CNM Health Institute with 100% of specificity and sensitivity. limit of detection 10 copies/reaction. Includes UNG enzyme to avoid contaminations and the kit is open system compatible with the most common extraction systems and RT-PCR platforms of the market.

More Less

Product category: Managed IT services, Tracking systems (RFID, RTLS), eHealth, telemedicine / telematics / telemetry, Healthcare information systems / software (HIS), Other administrative information systems / software, Intranet software, Image processing and archiving, imaging, OCR, DTP, RIS, PACS, Other medical information systems / software, Other equipment and devices for information and communication technology

AnaPath

Comprehensive management of anatomic pathology.
A global, functional and technical vision

More Less

ANAPATH A global, functional and technical vision v4

Company news

Date

Topic

01 Oct 2020

Vitro releases a PCR platform that multiplies the current diagnostic capacity of COVID-19

The combination of a new RNA extraction test, a SARS-CoV-2 RT-PCR test and a traceability software for the OT-2 Opentrons robots already available in over 15 large Spanish hospitals, will allow hospitals to optimize their use and multiply the current capacity to perform daily PCRs with their OT-2 robots in a fully automated way.
Vitro S.A. becomes the official distributor of Opentrons in Spain, and validates its reagents and software in the Opentrons robots located at the Virgen del Rocío University Hospital (Seville).
All Vitro’s reagents are produced in Spain. Additionally, Vitro is licensee of the extraction technology developed by the Carlos III Health Institute for the Opentrons platforms, and thus eliminating the dependence on the supply of tests and reagents manufactured outside Spain.
Besides, the new RT-PCR FluCovid test by Vitro released in August allows hospitals to differentiate patients infected with influenza from those infected with SARS-CoV-2 in a single test.

Madrid, October 01, 2020. Vitro S.A., the corporate group based in Seville and specialized in the development, manufacture and distribution of instruments, software and reagents for In Vitro Diagnostics (IVD), has just clinically validated its RNA extraction test -first step in the analysis of gene expression- and its RT-PCR-SARS-CoV-2 test so that, along with its own traceability software OpenVTS -designed to speed up and optimize processes- they can be used on the Opentrons robots already available in over 15 large Spanish hospitals achieving to multiply the current diagnostic capacity, which is key during these moments when new COVID-19 outbreaks are occurring.

Up to now, there was a lack of a comprehensive solution that prevented the optimization of the Opentrons robots for the diagnosis of COVID-19 in most hospitals: the lack of a technology capable of providing reagents, traceability software, optimized working protocols and the capacity to integrate these robots into the IT systems. These constraints have been finally solved by Vitro, whose reagents, protocol and software adapted to Opentrons allow performing hundreds of PCRs on a daily basis with just two OT-2 robots, multiplying the current capacity and allowing hospitals to scale their diagnostic capacity with the simultaneous use of 2 to 10 robots.

Vitro, with over 30 years of experience in the supply of reagents and diagnostic platforms to Spanish hospitals, has made major breakthroughs during the months in which the COVID-19 virus advanced in Spain. Therefore, it released a new RT-PCR test for SARS-CoV-2 in April, validated by the Carlos III Health Institute with 100% sensitivity and specificity, and in July it became the first company in the field of hospital diagnosis to commercialize a multiplex test capable of analyzing 23 virus causing respiratory diseases simultaneously, including the diagnosis of COVID-19. Lastly, in August it released its second RT-PCR Flu-Covid kit to the market, becoming the first company in the field to create a CE IVD kit capable of diagnosing Influenza A, Influenza B and SARS-CoV-2 (COVID-19) with the same test, allowing a differential diagnosis of these viruses in a key moment right before the beginning of the influenza season.

The CEO of Vitro, Javier Fernández, stated: “Vitro is one of the diagnostic test manufacturers in Spain that is strongly aiding the hospitals of our country in the diagnosis of COVID-19. We have already developed three different diagnostic tests for this virus in the last five months, proving our technological capacity to solve complex diagnostic needs in a short period of time. The development of a set of three tests, protocols and software by our company to implement them in the super-robots Opentrons, unique for their simplicity, sturdiness and low cost, allows multiplying the current capacity of processing PCRs at the hospitals where the Opentrons robots are used. This major improvement, along with the capacity of diagnosing infections with influenzaviruses and Covid simultaneously, the arrival of autumn and facing this second wave of infections, substantially strengthens the diagnostic capacity of our hospitals and diagnostic labs”.

Cost reduction and logistic enhancements

The experience of Vitro in molecular biology has allowed it to become the first licensee in the RNA extraction technology developed by the Carlos III Health Institute in Opentrons robots for the diagnosis of COVID-19. This new extraction technology, validated in thousands of clinical specimens, allows the hospitals to perform thousands of PCRs on a daily basis in an automated way using the OT-2 Opentrons robots. This capacity represents an enormous advantage in terms of cost reduction, and in addition, the national production of Vitro of this type of reagents is decisive in allowing the large hospitals in Spain to have a national supply source, avoiding the logistic problems of importing tests and reagents manufactured outside Spain.

In addition, the North American company Opentrons has signed a distribution contract with Vitro for its OT-2 robots for the Spanish market, thus recognizing the capacity of the Andalusian company to develop innovative hospital diagnostic platforms. Jon Martinez, director of sales at Opentrons, asserts: “Vitro has proven to be a very capable technological partner to help Spanish institutions and organizations to configure and optimize the use of our robots. We are very excited to continue working with Vitro to increase and improve the use of the Opentrons robotic platforms by new users in Spain who need the assistance and help of a local technological and industrial partner”.

The Virgen del Rocío University Hospital (Seville) has been the first hospital to benefit from an immediate and significant increase in its COVID-19 diagnostic capacity through the use of the "super-robots” Opentrons combined with Vitro’s PCR technology and reagents. The pharmacist specializing in Microbiology and Clinical Biochemistry, Pedro Camacho Martínez, as head of the section, has made an enormous effort, dedicating many hours of work in collaborating with Vitro to fine-tune its Opentrons robots, which has allowed the Microbiology Service to manage a significant increase in the number of PCRs processed each day: "The installation of Vitro technology and reagents in our Opentrons robots has allowed our hospital to considerably increase its capacity, which is essential in view of the increase in the number of PCRs to be performed every day for the diagnosis of COVID-19".

Vitro is in the phase of implementing this important technological improvement in a large part of the rest of the Opentrons-user hospitals, and is awaiting the possible award by INGESA of the supply of Opentrons robots and Covid technology, protocols and diagnostic reagents developed by Vitro and the Carlos III Health Institute to the rest of the Spanish healthcare sector.

The impact of Vitro's technology, reagents, protocol and software in a hospital that has, for example, 8 Opentrons robots, working 24 hours a day, would allow its diagnostic laboratory to perform up to 4500 PCRs daily with minimal staff intervention. Thus, hospitals have great flexibility to increase or decrease this capacity, increasing or reducing the Opentrons OT-2 robots used simultaneously as needed.

More Less

https://www.vitro.bio/Covid-19/Noticia/Diagnostico/PlataformaPCR

Vitro, Solutions for Opentrons

14 Jul 2020

Vitro releases a new in vitro diagnostic test for the simultaneous detection of the virus of the COVID-19 and other 20 respiratory pathogens

The multiplex test “Respiratory Flow Chip” allows diagnostic laboratories to identify the virus or bacterium causing the
Vitro S.A. is the first company worldwide to commercialize a test covering such a large respiratory viral panel, including SARS-CoV-2.

Madrid, July 14, 2020. Vitro S.A., the Spanish corporate group specialized in the development, manufacture and distribution of In Vitro Diagnostic (IVD) instruments, software and reagents, has released a new In Vitro Diagnostic test, named “Respiratory Flow Chip” to detect 21 respiratory pathogens simultaneously, including 18 viral species, SARS-CoV 2 and three bacterial species. This way, it becomes the first company worldwide to commercialize a test covering such a large respiratory viral panel.

This new IVD kit for the identification of the nucleic acids of SARS-CoV-2 and other 20 pathogens causing the main acute respiratory infections is highly sensitive and specific. It has a very high value, since it allows identifying, in a single laboratory test, the virus causing the respiratory infection, and thus shortening diagnostic times and simplifying decision-making in terms of isolation of the patient depending on the type of virus causing the infection.

The test commercialized by Vitro is performed on samples of nasopharyngeal smear or bronchoalveolar lavages from people suspected of COVID-19. Once the sample has been collected by healthcare workers with the “Respiratory Flow Chip” kit, it is processed in the diagnostic laboratories in a quick and fully automated way. This test includes all the necessary reagents to treat the sample, including the capture chip where the genome sequences specific to the 21 pathogens under study are located. Besides detecting the SARS-CoV-2, the new test also identifies the Influenza A virus. Influenza B virus, Respiratory Syncytial Virus, Rhinovirus, Enterovirus, Human Parainfluenza Virus, Adenovirus, Metapneumovirus and the bacteria Bordetella pertussis and parapertussis and Mycoplasma pneumoniae.

The “Respiratory Flow Chip” test is processed automatically by the robotized instruments hybriSpotTM, which combine the PCR technique and the reverse flow-through technology. This way, the new Vitro’s product allows analyzing up to 24 samples from patients simultaneously, issuing the result report in less than 3 hours.

The hybriSpotTM platforms offer a versatile, effective and economic solution for the simultaneous diagnosis of the genetic material from these respiratory pathogens and other panels of multiple pathogens causing diverse diseases. Moreover, these robots are enhanced and manufactured by Vitro at its facilities in Seville, where the management and analysis software for all the tests that make up its hybriSpotTM product portfolio are also developed. Vitro designs and produces all the tests and reagents by itself at its facilities in Granada. These diagnostic platforms have the CE-IVD marking and are currently commercialized both in Spain and in over 30 countries.

The “Respiratory Flow Chip” test is the third diagnostic test commercialized by Vitro in Spain aimed at fighting COVID-19. The corporate group in Seville has developed and commercializes a RT-CPR test to detect the nucleic acid of SARS-CoV-2, which was validated by the Carlos III Health Institute with 100% sensitivity and specificity. Additionally, and according to the distribution activity Vitro does selectively for some foreign manufacturers of IVD platforms and tests, the company distributes exclusively in Spain the serology-based test for the detection of IgM and IgG antibodies in blood against SARS-CoV-2 produced by the manufacturer Snibe (China). It has recently introduced in Spain the first certified kit for the detection of SARS-CoV-2 neutralizing antibodies, produced by the manufacturer Genscript and thus strengthening its portfolio of serology-based tests.

During the first three months of the health crisis, the IgM and IgG tests against the COVID-19 supplied by Vitro and manufactured by Snibe have covered 40% of the health needs in Spain. In this regard, Javier Fernandez, CEO of Vitro S.A, states: “Thanks to the infrastructure of our baseline laboratory in Granada, we are currently validating innovative diagnostic tests for SARS-CoV-2 using several technologies, including not only the PCR technologies, but also flow cytometry and other alternative technologies for the detection of both the RNA of the virus and the antibodies developed against the virus, which makes Vitro's capacity to develop and supply different diagnostic tests and technologies for Covid-19 unique within our National Health System”. These new diagnostic tests will be available soon and will allow Spain’s hospital network to have the most cutting-edge diagnostic tools against SARS-CoV-2 currently available.

More Less

https://www.vitro.bio/Covid-19/Noticia/Diagnostico/RespiratoryFlowChip

Vitro Test Launch

About us

Company portrait

We are a Spanish corporation specialized on development, manufacturing and distribution of instruments, software and in vitro diagnostic (IVD) reagents by applying non-invasive techniques, typically used in immunohistochemistry and molecular biology. We commercialize CE-marked IVD multiplex tests for HPV, sepsis diagnosis, AMR, ETS, respiratory viruses and Zoonosis. Additionally, we have extensive experience in PCR-multiplex technology by reverse flow hybridization.

We are determined to technological innovation and personalized treatments, offering the best solutions for IVD diagnosis in different areas. Our main goal is definitely to improve the health status for every patient and in order to achieve this, we are willing to work under the highest quality standards, looking for the excellence of our products and services.
More importantly, we have a highly committed and qualified team to offer the best service and most efficient and accurate diagnostic solutions, adapted to each client’s requirements.

Your health, our goal

Company data

Sales volume 10-49 Mio US $

Export content max. 50%

Number of employees 100-499

Foundation 1989

Area of business Diagnostics

Company information as a PDF file

PDF

Vitro - Dossier

Vitro S.A. (VitroGroup)

Submit your contact details

Please log in

An error has occurred

Message has been sent

Trade fair planning

Contact

Beatriz De la Fuente

Miguel Ángel Viribay

Marta Varela

Sergio Tirado

Please log in

Please log in for matchmaking

Let's get started!

Our range of products

Product categories

Our products

RESPIRATORY FLOW CHIP

HPV DIRECT FLOW CHIP

STD DIRECT FLOW CHIP

SEPSIS FLOW CHIP

AMR DIRECT FLOW CHIP

BACTERIAL CNS FLOW CHIP

TICK-BORNE BACTERIA FLOW CHIP

IHC antibodies

FISH probes

MD Stainer

Hybrispot 12 PCR Auto

SARS-Cov-2 RT-PCR Kit

FLU-COVID RT-PCR kit

RESPIPLEX RT-PCR Kit

AnaPath

Company news

About us

Company portrait

Company data

Company information as a PDF file